XT
PRLD icon

XTX Topco’s Prelude Therapeutics PRLD Stock Holding History

XTX Topco’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-57,190
Closed -$196K – 4589
2026
Q1 		$196K Buy
57,190
+7,031
+14% +$18.4K ﹤0.01% 2849
2025
Q4 		$145K Buy
50,159
+34,581
+222% +$58.4K ﹤0.01% 2521
2025
Q3 		$22.4K Sell
15,578
-26,995
-63% -$27.1K ﹤0.01% 2305
2025
Q2 		$34.5K Buy
42,573
+17,873
+72% +$15.5K ﹤0.01% 2079
2025
Q1 		$19K Sell
24,700
-13,639
-36% -$12.7K ﹤0.01% 2147
2024
Q4 		$48.9K Sell
38,339
-9,900
-21% -$13.1K ﹤0.01% 1900
2024
Q3 		$99.9K Buy
+48,239
New +$223K 0.01% 1609

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

XTX Topco's PRLD Position: Q2 2026 in Review

XTX Topco sold out of Prelude Therapeutics (PRLD) in Q2 2026, closing a stake of 57,190 shares — an estimated $196K sold.

XTX Topco first reported a position in PRLD in Q3 2024 and held it in 7 quarters. The position peaked at $196K in Q1 2026. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • XTX Topco reported no remaining Prelude Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 57,190 Prelude Therapeutics shares in Q2 2026, an estimated $196K.
  • XTX Topco first reported a position in Prelude Therapeutics in Q3 2024 and held it in 7 quarters.
  • XTX Topco's Prelude Therapeutics position peaked at $196K in Q1 2026.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.